Capital Advisory Group Advisory Services’s AstraZeneca AZN Stock Holding History

Capital Advisory Group Advisory Services’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-79	Closed	-$10K	–	230
2022 Q1	$10K	Buy	+79	New	+$9.47K	﹤0.01%	364
2021 Q4	–	Sell	-79	Closed	-$9K	–	196
2021 Q3	$9K	Buy	79 +57	+259%	+$6.63K	﹤0.01%	397
2021 Q2	$3K	Hold	22	–	–	﹤0.01%	485
2021 Q1	$2K	Hold	22	–	–	﹤0.01%	476
2020 Q4	$2K	Hold	22	–	–	﹤0.01%	481
2020 Q3	$2K	Hold	22	–	–	﹤0.01%	437
2020 Q2	$2K	Hold	22	–	–	﹤0.01%	415
2020 Q1	$2K	Buy	+22	New	+$2.07K	﹤0.01%	364
2019 Q4	–	Sell	-22	Closed	-$2K	–	216
2019 Q3	$2K	Hold	22	–	–	﹤0.01%	382
2019 Q2	$2K	Hold	22	–	–	﹤0.01%	370
2019 Q1	$2K	Hold	22	–	–	﹤0.01%	367
2018 Q4	$2K	Hold	22	–	–	﹤0.01%	340
2018 Q3	$2K	Hold	22	–	–	﹤0.01%	325
2018 Q2	$2K	Buy	+22	New	+$1.58K	﹤0.01%	309

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $53.8B AUM 19.23% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital Advisory Group Advisory Services's AZN Position: Q2 2022 in Review

Capital Advisory Group Advisory Services sold out of AstraZeneca (AZN) in Q2 2022, closing a stake of 79 shares — an estimated $10K sold.

Capital Advisory Group Advisory Services first reported a position in AZN in Q2 2018 and held it in 14 quarters. The position peaked at $10K in Q1 2022. 1,015 funds tracked by Wall St. Rank hold AZN as of Q2 2022.

Capital Advisory Group Advisory Services reported no remaining AstraZeneca position as of Q2 2022 after selling out during the quarter.
Capital Advisory Group Advisory Services sold 79 AstraZeneca shares in Q2 2022, an estimated $10K.
Capital Advisory Group Advisory Services first reported a position in AstraZeneca in Q2 2018 and held it in 14 quarters.
Capital Advisory Group Advisory Services's AstraZeneca position peaked at $10K in Q1 2022.
1,015 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2022.

Based on Capital Advisory Group Advisory Services's 13F filing for Q2 2022, filed 12 Aug 2022.